Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2002

View Archived Issues

Novel class of ring-contracted macrolide antibiotics presented by Enanta

Antibiotic research at Enanta focused on 14-membered ring macrolides

EVP-1001-1 completes phase I

Reduction of RCN incidence with fenoldopam mesilate after contrast angiography

RS-1178, a potential new drug for Alzheimer's disease

GEM-231 reported to increase the antitumor efficacy of irinotecan

Wyeth selects compound in women's healthcare for development pipeline

Wakunaga presents new inhibitors of MTP for lipid disorders

Novel hypolipidemic agents with multiple mechanisms of action described by Takeda

Celltech claims novel P2Y agonists for COPD and other conditions

Ulcerative colitis drug TC-2403-12 completes phase I

Novel cannabinoid CB2 agonists in early development at Schering-Plough

Arrow and Toyama enter antifungal discovery collaboration

Two anidulafungin trials complete enrollment

InterMune and Maxygen advance development of once-weekly Actimmune

New program for TLK-286 in combination with chemotherapy

Genentech returns rights to SGN-14 to Seattle Genetics

NMDA agonist with potential in the treatment of alcohol abuse

Novel 5-HT1A receptor ligand with anxiolytic and potential antidepressant/procognitive effects

Initial clinical pharmacokinetic and safety data reported for LY-450108

Bacterial enzyme selected as a target for novel antibiotics at Arpida

Inhibitors of essential Gram-negative metalloenzyme LpxC identified at Versicor

GeneSoft's HARPs show suitable efficacy and PK profiles for further development

Effective attenuation of status epilepticus in rats treated with NS-1209

Antiepileptic efficacy and safety of AWD-34-176 demonstrated in rodent models

Filing of additional data for gepirone delayed until next year

Factor Xa inhibitors in early development at Boehringer Ingelheim